BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37407475)

  • 1. [Classic Hodgkin lymphoma].
    Makita S
    Rinsho Ketsueki; 2023; 64(6):504-513. PubMed ID: 37407475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
    Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
    Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Therapies in the Treatment of Hodgkin Lymphoma.
    Andrade-Gonzalez X; Ansell SM
    Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
    Ferhanoglu B; Ozbalak M
    Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin lymphoma: Focus on evolving treatment paradigms.
    Roswarski JL; Longo DL
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
    Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
    Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
    Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
    Front Immunol; 2021; 12():756583. PubMed ID: 35095839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial.
    Hochberg J; Basso J; Shi Q; Klejmont L; Flower A; Bortfeld K; Harrison L; van de Ven C; Moorthy C; Islam H; Gerard P; Voss S; Cairo MS
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35584865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment strategy for newly diagnosed Hodgkin lymphoma: current evidence].
    Kusumoto S
    Rinsho Ketsueki; 2018; 59(10):2117-2126. PubMed ID: 30305517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
    Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
    J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted therapy for advanced-stage Hodgkin lymphoma.
    Spinner MA; Advani RH
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):200-206. PubMed ID: 30504311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
    Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
    Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.